Sun Pharma
Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full
India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
2 min read4 Aug 2026Govt, pharma industry lean on trade talks to soften Trump’s drug tariff plan
The US is India’s largest pharmaceutical export market, accounting for $9.47 billion, or 30.4%, of the country’s total pharmaceutical exports of $31.12 billion in FY26, making the proposed tariffs one of the biggest risks facing the sector.
5 min read25 Jul 2026SBI steps in with $1-billion funding for Sun Pharma’s Organon deal
The size of SBI’s funding for the $12-billion Sun Pharma-Organon deal underscores the growing appetite among state-run banks to back M&A deals by Indian companies.
1 min read9 Jun 2026Sun Pharma guides for slower FY27 growth amid regulatory, macro challenges
Sun Pharma forecasts high single-digit revenue growth for FY27 after an 11.9% increase in FY26 revenue. The company aims to expand its innovative portfolio amid regulatory challenges and compliance issues, while also focusing on acquisitions and new product launches in the obesity-drug market.
4 min read22 May 2026Sun Pharma Q4 results 2026: Profit jumps 26% YoY to ₹2,714 crore; recommends final dividend of ₹5 for FY26
Sun Pharma Q4 results 2026: Profit jumped 26% YoY to ₹2,714 crore. Total revenue from operations for the quarter under review rose 12.8% YoY to ₹14,611.79 crore. Sun Pharma's board recommended a final dividend of ₹5 per share of ₹l each.
1 min read22 May 2026Son rise at Sun: Decoding the architecture of Dilip Shanghvi’s global empire
With a bold $11.75 billion bet on Organon, Dilip Shanghvi is hedging a decade of US stagnation and quietly commissioning an empire for a son who would rather let the numbers do the talking.
1 min read6 May 2026Sun Pharma’s deal to buy Merck-spinoff Organon ticks the right box on acquisition cost if not R&D
Sun Pharma’s acquisition of US-based Organon looks like a financial bargain for the global scale and market access it offers. But the Indian drugmaker may need to look elsewhere for an R&D boost that could put it at the cutting edge of healthcare.
2 min read28 Apr 2026Sun Pharma’s Organon buy took shape over three months of intense negotiations
After intense negotiations, Sun Pharma is set to acquire Organon for $11.75 billion, marking a significant milestone for Indian overseas acquisitions. The deal aims to strengthen Sun Pharma's global footprint and enhance its offerings in women's health and biosimilars.
2 min read28 Apr 2026How big is Organon’s biosimilar push for Sun Pharma?
The Organon acquisition positions Sun Pharma in the global biosimilars market amid efforts to monetize biologics patent expiries.
2 min read28 Apr 2026Sensex, Nifty 50 snap 3-day losing run, end over 0.8% higher — 10 key highlights from the Indian stock market today
Buying in Sun Pharma, index heavyweight Reliance Industries and select banking and IT counters drove Sensex and Nifty 50 higher even as the headwinds emanating from the US-Iran war lingered.
4 min read27 Apr 2026Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.